Axel Hauschild

Axel Hauschild has co-led critical adjuvant melanoma trials including COMBI-AD and has been a leading investigator in multiple registration studies of targeted therapy and immunotherapy for melanoma. His research has characterized long-term relapse-free and overall survival in patients receiving adjuvant dabrafenib plus trametinib for resected BRAF V600-mutated stage III melanoma. He has studied biomarkers predicting adjuvant BRAF/MEK inhibitor outcomes and optimal sequencing strategies when patients relapse after adjuvant targeted therapy. His contributions to European melanoma clinical trial infrastructure have accelerated the development and approval of new adjuvant and metastatic melanoma treatments.